[Form 4] Nuvectis Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 Overview: On 06/20/2025, Charles Mosseri-Marlio, a 10% owner of Nuvectis Pharma, Inc. (NVCT), filed a Form 4 disclosing an open-market purchase of 5,603 shares of the company’s common stock at a price of $7.99 per share. The transaction was executed indirectly through Emerald Hill Ventures SARL SPF, an entity Mosseri-Marlio beneficially owns.

Following the purchase, the insider’s aggregate ownership rose to 2,981,806 shares held indirectly and 109,321 shares held directly. The filing lists transaction code "P," signifying a standard open-market purchase. No sales, derivative security activity, or 10b5-1 plan indications were reported.

The additional shares represent less than 0.2% of Mosseri-Marlio’s total reported holdings but still reflect continued alignment with public shareholders. The filing contains no operational updates or financial metrics beyond the share purchase details.

Positive

• Insider purchase of 5,603 NVCT shares at $7.99 indicates continued shareholder alignment.

Negative

• Purchase size is <0.2% of existing holdings, suggesting minimal immediate market impact.

Insights

Financial Analyst

TL;DR: Small insider buy; positive sentiment but limited market impact.

The 5,603-share purchase (≈US$44.8k) increases Mosseri-Marlio’s indirect stake by only 0.19%. Insider buying generally signals confidence, and the absence of concurrent sales or hedging instruments supports a benign outlook. However, given his existing 3.1 million-share position and NVCT’s trading volume, the transaction is too small to materially affect valuation or float. Investors may view it as a mild vote of confidence rather than a catalyst.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mosseri Marlio Charles

(Last) (First) (Middle)

27 RIPPLEVALE GROVE

(Street)

LONDON N1 1HS

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		P		5,603	A	$7.99	2,981,806(1)	I	By Emerald Hill Ventures SARL SPF.
Common Stock								109,321	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Charles Mosseri Marlio is the beneficial owner of Emerald Hill Ventures SARL.

	/s/ Charles Mosseri-Marlio	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the NVCT Form 4 filed on 06/24/2025 disclose?

It reported that 10% owner Charles Mosseri-Marlio purchased 5,603 shares of Nuvectis Pharma common stock at $7.99 each.

How many NVCT shares did Charles Mosseri-Marlio buy?

He acquired 5,603 shares.

At what price were the NVCT shares purchased?

The shares were bought at $7.99 per share.

What is the insider’s total ownership after the transaction?

Mosseri-Marlio now owns 2,981,806 shares indirectly and 109,321 shares directly.

What does transaction code "P" mean in the Form 4?

Code "P" designates a regular open-market purchase of shares.

Were any derivative securities involved in this filing?

No, the filing shows no derivative security transactions.